New Treatment Options for Rare Diseases in the Soft Tissue

New Treatment Options for Rare Diseases in the Soft Tissue

Episodes

Specialty:

All

Year:

All

EP. 1: Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

EP. 2: Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

EP. 3: Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

EP. 4: The Prognostic Value of Molecular Testing

March 25th 2020

EP. 5: Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

EP. 6: Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020

EP. 7: Use of Targeted Therapy in GIST Mutations

March 25th 2020

EP. 8: GIST Treatment: Durability of Response and Challenges

March 25th 2020

EP. 9: The Future of Treatment for Soft Tissue Diseases

March 25th 2020

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma